News Post 05-12-2020

Biotype consolidates multiple glioma markers on one platform

New approaches to detect different genetic aberrations such as point mutations (IDH1/IDH2), copy number variations (1p/19q co-deletion), and gene expression (ATRX)

Biotype, together with a clinical cooperation partner, is right now developing a Modaplex panel to detect different genetic aberrations in one single run using synchronized PCR multiplex technologies.

Molecular-based classification of brain tumors has become routine practice since the WHO classification was updated in 2016. Currently, due to the different biological nature of these aberrations, several testing methods need to be performed in a step-wise procedure. Among those are immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and loss of heterozygosity (LOH) analysis, and different sequencing approaches.

Utilizing the Modaplex™ multiplexing technology, a prototype panel, which allows the simultaneous analysis of:

  • point mutations (IDH1/IDH2),
  • copy number variations (1p/19q co-deletion),
  • and gene expression (ATRX)

in one single run, has been established and tested in a feasibility phase.

The current research status is going to be published in a poster at the virtual ESP congress 2020, taking place from December 6th to 9th. Have a look at the virtual poster platform to get more information on “Establishing and validating of multiple glioma markers on a single molecular platform.”